Nutra Pharma Corp. (PK:NPHC)
Business Focus: Biotechnology & Medical Research
Mar 22, 2024 04:39 pm ET
Nutra Pharma Corp. Reaches Settlement with SEC
Nutra Pharma Corporation (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) earlier this week. On March 19, 2024, the United States District Court for the Eastern District...
Mar 23, 2022 09:15 am ET
Nutra Pharma Announces First Manufacturing Agreement
Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Mar 17, 2022 09:15 am ET
Nutra Pharma Expands Manufacturing Capabilities
Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Jan 18, 2022 12:44 pm ET
Nutra Pharma Letter to Shareholders
Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Jul 26, 2021 10:30 am ET
Nutra Pharma Provides Business and Compliance Updates
Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Jul 23, 2021 09:14 am ET
Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures
Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Jul 15, 2021 08:30 am ET
Nutra Pharma Engages Government Affairs Consulting Firm
Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple...
Jun 08, 2021 06:00 am ET
Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings
Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin(R) line of pain relief products to their marketplace
Jun 04, 2021 08:15 am ET
Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers
Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs
Jun 02, 2021 08:56 am ET
Professional Snowboarder Jake Vedder Joins Nutra Pharma in Endorsing Nyloxin for Chronic Pain Relief
Nutra Pharma announces that professional snowboarder and wakeboarder, Jake Vedder, is endorsing Nyloxin for Chronic Pain Relief as part of their social media and influencer campaign
May 27, 2021 09:00 am ET
Nutra Pharma Provides Updates on Improvements of Manufacturing Capabilities
Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for the production of their over-the-counter pain relievers
May 24, 2021 09:45 am ET
Nutra Pharma Announces Influencer and Social Media Campaign for Nyloxin and Pet Pain-Away
Nutra Pharma is announcing their newest marketing plans for their over-the-counter pain relievers will utilize influencers, celebrities and athletes on social media platforms
Apr 15, 2021 09:00 am ET
Nutra Pharma is Excited to Announce: Luxury Feet now Available on Amazon
Nutra Pharma is announcing their newest product, Luxury Feet; is now available for purchase on Amazon.com
Mar 16, 2021 08:30 am ET
Nutra Pharma Announces Distribution of Luxury Feet for the Relief of Pain from High Heels
Nutra Pharma is announcing the marketing and distribution plans for Luxury Feet; an over-the-counter pain reliever for women who experience pain or discomfort due to high heels and stilettos
Mar 11, 2021 08:30 am ET
Nutra Pharma Engages Quality and Regulatory Professionals Ahead of Clinical Trials
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation in preparation of expanded OTC sales and clinical trials
Feb 23, 2021 09:20 am ET
Nutra Pharma Provides Updates on Laboratory Upgrades and Certifications
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation
Feb 12, 2021 08:45 am ET
Nutra Pharma Announces New Intellectual Property Update and Engages Additional Intellectual Property Attorneys
Plantation, Florida--(Newsfile Corp. - February 12, 2021) - Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they are focusing on their intellectual property portfolio and have engaged their IP attorneys at Christopher & Weisberg P.A.
Jan 12, 2021 10:22 am ET
Nutra Pharma Letter to Shareholders
Plantation, Florida--(Newsfile Corp. - January 12, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company's website.
Nov 18, 2020 09:15 am ET
Nutra Pharma Provides Updates on Progress of their Nerve Agent Countermeasures
Nutra Pharma is providing updates on their work in utilizing their platform technology as potential countermeasures against nerve agents
Nov 11, 2020 07:15 am ET
Nutra Pharma Announces Nyloxin Now Available on the Walmart Marketplace
Nutra Pharma announces that its all-natural pain reliever, Nyloxin, has been accepted by the Walmart Marketplace and is now available there for purchase
Nov 04, 2020 09:00 am ET
Nutra Pharma Provides Financing Updates and the Elimination of Institutional Debt
Nutra Pharma is providing updates regarding debt restructuring and financing plans
Nov 03, 2020 08:30 am ET
Nutra Pharma Provides Business and Compliance Updates
Nutra Pharma is providing updates regarding their business plans, accounting and compliance.
Mar 03, 2020 08:30 am ET
Nutra Pharma Provides Updates on Marketing and Distribution
Nutra Pharma is providing updates regarding the marketing and distribution of the Company's Over-the-Counter products: Nyloxin, Pet Pain-Away and Equine Pain-Away
May 30, 2019 08:30 am ET
Nutra Pharma Announces that Nyloxin is Now Available on the iRemedy Marketplace
via OTC PR WIRE -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the iRemedy Healthcare Companies has added the entire...
Apr 10, 2019 08:30 am ET
Nutra Pharma Responds to FDA Warning Letter
via OTC PR WIRE -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company has responded to an FDA warning letter...
Sep 28, 2018 05:58 pm ET
Nutra Pharma Comments on SEC Complaint
via OTC PR WIRE -- Nutra Pharma Corporation (OTC: NPHC), provided the following comment on the lawsuit filed by the U.S. Securities and Exchange Commission earlier today. Nutra Pharma Corporation learned today that the Securities and Exchange...
Sep 25, 2018 08:30 am ET
Nutra Pharma announces updates with EuroAmerican IP & BioArmor, LLC, a Service-Disabled Veteran-Owned Small Business for Sales through GoVets.com
via OTC PR WIRE -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that their work with EuroAmerican IP, LLC has resulted in a...
Jul 17, 2018 08:30 am ET
Nutra Pharma Announces Agreement to Launch Comprehensive Internet Marketing Campaign
via OTC PR WIRE-- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that it has executed an agreement with American Marketing...
Jul 03, 2018 08:30 am ET
Nutra Pharma Announces Direct Mail Campaign for Pet Pain-Away™ Private Label Brand
Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that DEG Productions has signed an exclusive distribution deal with one of the...
Jun 28, 2018 08:30 am ET
Nutra Pharma Signs Definitive Letter of Intent for $4 Million Joint Venture Financing
via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human...
Jun 06, 2018 08:30 am ET
Nutra Pharma Announces Direct Response Television Campaign for Pet Pain-Away™
via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that DEG Productions has initiated a re-launch of its...
Apr 19, 2018 08:30 am ET
Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution
Nutra Pharma is partnering with NxGen Brands, LLC to market and distribute their Over-the-Counter (OTC) pain reliever, Nyloxin® through all of their distribution channels
Apr 10, 2018 08:30 am ET
Nutra Pharma Files Provisional Patent for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
CORAL SPRINGS, Fla., April 10, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments...
Mar 08, 2018 08:30 am ET
Nutra Pharma Announces Corporate Updates
Nutra Pharma is announcing today the first of several restructuring steps that will expand the Company’s core business strengths, restructure debt as well as increase its reach into important commercial markets
Feb 21, 2018 08:30 am ET
Nutra Pharma Files Provisional Patent for Nerve Agent Counter Measures
CORAL SPRINGS, Fla., Feb. 21, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing...
Feb 01, 2018 08:30 am ET
Nutra Pharma Announces Nyloxin® Distribution Agreement for Australia and New Zealand
Nutra Pharma has announced that they have signed a definitive Distribution Agreement with Pharmachal PTY LTD to distribute Nyloxin® in Australia and New Zealand
Jan 25, 2018 08:30 am ET
Nutra Pharma Unveils Updated Websites
Nutra Pharma Corporation is inviting visitors to explore its new websites at www.nutrapharma.com and www.nyloxin.com. The new websites have been designed to provide the ultimate user-friendly experience with improved navigation and functionality throughout.
Jan 18, 2018 09:45 am ET
Nutra Pharma Partners with EuroAmerican IP to Distribute Nyloxin® for Sale to Government Agencies
Nutra Pharma is partnering with EuroAmerican IP, LLC to distribute their Over-the-Counter (OTC) pain reliever, Nyloxin® Topical Gel, through EuroAmerican IP’s existing Federal Supply Schedule #V797D-40251
Dec 29, 2017 03:36 pm ET
Nutra Pharma Letter to Shareholders
Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company
Aug 03, 2017 08:30 am ET
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the textbook, Multimodal Management of Canine Osteoarthritis, Second Edition, includes references to Nutra Pharma's development of cobra venom-based products for treating pain in dogs.
Jun 21, 2017 08:30 am ET
Nutra Pharma Announcing Launch of Luxury Feet
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that they are expanding their product line with the introduction of Luxury Feet; an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos.
Jun 07, 2017 08:30 am ET
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company and their products were featured in an interview aired last night on the Univision network's Spanish-language news show, Primer Impacto (www.primerimpacto.com).
May 31, 2017 08:30 am ET
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration today with the University of Maryland Bioprocess Scale-Up Facility (BSF) to optimize manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis.
May 23, 2017 08:30 am ET
Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration today with International Security Group to develop its nerve agent counter measures.
Mar 14, 2017 08:30 am ET
Nutra Pharma CEO Rik Deitsch Interviewed by Stockguru.com
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Stockguru.com will be releasing an interview with Nutra Pharma's CEO through their website.
Feb 22, 2017 08:30 am ET
Global Small Caps Initiates Coverage on Nutra Pharma
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.
Feb 15, 2017 08:30 am ET
Nutra Pharma and Nyloxin Featured on NBC News-Miami
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company and their products were featured in an interview aired last night on Miami's NBC News affiliate (www.nbcmiami.com).
Dec 27, 2016 08:30 am ET
Nutra Pharma Letter to Shareholders
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nov 15, 2016 08:30 am ET
Nutra Pharma Announces Infomercial Campaign for Pet Pain-Away(TM)
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that DEG Productions has initiated an infomercial test campaign of Nutra Pharma's Over the Counter (OTC) drug for the treatment of pain in companion animals, Pet Pain-Away™. Last week, the Company announced a license agreement with DEG Productions for the marketing
Nov 09, 2016 08:30 am ET
Nutra Pharma Announces Licensing and Marketing Agreement for Pet Pain-Away(TM)
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have signed an agreement with DEG Productions for the marketing and distribution of their Over the Counter (OTC) drug for the treatment of pain in companion animals, Pet Pain-Away™.
Sep 14, 2016 09:16 am ET
Nutra Pharma Announces Manufacturing Alliance With Omnia Biologics to Produce RPI-78M for Clinical Trials in Pediatric Multiple Sclerosis
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a manufacturing alliance today with Omnia Biologics to clone and produce alpha-cobratoxin for the production of RPI-78M for upcoming clinical trials in Pediatric Multiple Sclerosis.
Aug 30, 2016 08:30 am ET
Nutra Pharma Announces Addition of Maj. Gen. Kenneth Dowd to Its Advisory Board
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today the appointment of Maj. Gen. Kenneth Dowd, US Army (Ret.) as Strategic Advisor for the Company's newly created 'Military & Veterans' business segment. General Dowd will support Nutra Pharma's efforts in presenting the Company's non-opiate, non-narcotic over-the-counter (OTC) pain solution, Nyloxin® to the US Military and the Veteran's Administration.
Aug 16, 2016 08:30 am ET
Nutra Pharma Announces Additions to the Board of Directors and Management Team
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today the appointment of Dan Oran as their newest member of their Board of Directors. They are also announcing the appointment of Dale Vanderputten, PhD as their Chief Scientific Officer (CSO).
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.